Advancing degrader and proximity-based drug development

https://www.news-medical.net/industry-focus/Advancing-degrader-and-proximity-based-drug-development?utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=drug_discovery_newsletter_3_september_2026 A decade of development has yielded the targeted protein degradation (TPD) field its first drug approval with Arvinas' Veppanu. Alongside the 2026 market resurgence, this clinical achievement is poised to inspire novel strategies and elevate TPD to a major milestone. Targeted protein degradation is reshaping drug discovery, from PROTACs to molecular glues and proximity-based approaches. This eBook explores the scientific, technical, and development considerations helping teams identify stronger candidates, improve selectivity, and accelerate therapeutic innovation across complex disease areas where conventional modalities may fall short for patients worldwide today.